Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.

Join us as we dived into four pivotal studies:

• frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities.

• POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice?

• High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols.

• EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.

Listen us on:

• Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://x.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in for an insightful discussion on these important studies and their potential impact on clinical practice. Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!

#Lymphoma, #DLBCL, #EHA2026, #Hematology, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials.

Key topics covered in this episode include:

• Overview of the recent FDA approvals for antibody-drug conjugates (ADCs) in breast cancer
• Detailed discussion on the ASCENT-04 trial focusing on PD-L1–positive metastatic triple-negative breast cancer
• Insights into the ASCENT-03 trial for PD-L1–negative disease
• Comparison of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), including their efficacy and side effect profiles
• Management strategies for common side effects such as neutropenia and diarrhea

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• ⁠X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

In this ASCO 2026 Highlights discussion we dived into the latest advancements in breast cancer space. In this episode, we welcomed back Dr. Hope Rugo to discuss key studies that are shaping the future of breast cancer treatment.

Episode Highlights:

• OPTIMA: Discover how the Prosigna genomic assay could change the approach to adjuvant chemotherapy in hormone receptor-positive breast cancer.

• lidERA Update: Learn about the promising results of giredestrant, an oral SERD, and its potential role in adjuvant settings.

• VIKTORIA-1: Exploring the implications of gedatolisib for PIK3CA mutated disease and its impact on progression-free survival.

• Triple Negative Breast Cancer: Insights on the final overall survival updates from the KEYNOTE-522 and the exciting developments in antibody-drug conjugates (ADCs) like sasitizumab through ASCENT-03 and ASCENT-04 studies, and datopotamab from TROPION-Breast02 study.

Listen us on:

Apple Podcast:

https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• ⁠X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Hope this episode provided the very needed updates from ASCO 2026 focusing on the breast cancer world. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#BreastCancer #ASCO2026 #ClinicalTrials #PrecisionOncology#OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.

Join us as we dived into:

• The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
• Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from the MajesTEC-3 and MajesTEC-9 studies.
• The promising data around talquetamab from the MonumenTAL-3 study, highlighting its significant progression-free survival (PFS) improvement.
• An overview of mezigdomide, a new immunomodulatory agent, and its impact on treatment strategies for anti-CD38 and lenalidomide-refractory patients.

We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.

Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!

Listen to us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.

Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.

Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.

Topics Covered:

• Current treatment options for relapsed multiple myeloma

• Insights from the MajesTEC-3 and MajesTEC-9 studies

• The role of bispecific antibodies and CAR-T therapies

• Managing side effects and patient care strategies

• The importance of community and academic partnerships

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in now and stay informed about the latest in oncology!

#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs,#OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.

We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.

Key topics covered in this episode included:

• The role of next-generation sequencing (NGS) in guiding treatment options
• Choosing between dual checkpoint inhibitors and IO-TKI combinations
• Managing side effects associated with various treatment regimens
• Sequencing treatment options for patients who progress after initial therapy
• Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!

#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI,#OncologyBrothers

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.

In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space:

• PROTEUS: trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm.
• TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance.
• CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study.
• EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up.
• POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population.
• LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice.

#GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer,#RenalCellCarcinoma, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.

Join us as we explore:

• The framework for balancing systemic therapy with different types of radiation, including SBRT, palliative, and conventional radiation.
• Insights on managing cytotoxic chemotherapy, immunotherapy, TKIs, and targeted therapies in conjunction with radiation.
• The importance of individualized treatment plans and the evolving data around various drug classes, including BRAF inhibitors, PARP inhibitors, and anti-HER2 therapies.
• Practical recommendations for community oncologists navigating these complex decisions.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to check out Dr. Sanford's teaching video for more in-depth information!

#RadiationOncology, #SystemicTherapy, #SBRT,#MultidisciplinaryCare, #OncologyBrothers